INMED PHARMACEUTICALS INC. Amortization of Intangible Assets
INMED PHARMACEUTICALS INC. (INM) reported Amortization of Intangible Assets of $162.64 thousand for the 12-month period ending 2026-06-30, per its S-4/A filed 2026-09-09.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-09-09
- INMED PHARMACEUTICALS INC. amortization of intangible assets for the quarter ending 2026-06-30 was $40.64K, a 0.00% change year-over-year.
- INMED PHARMACEUTICALS INC. amortization of intangible assets for the quarter ending 2026-03-31 was $41.00K, a 0.00% change year-over-year.
- INMED PHARMACEUTICALS INC. amortization of intangible assets for the quarter ending 2025-12-31 was $41.00K, a 0.00% change year-over-year.
- INMED PHARMACEUTICALS INC. amortization of intangible assets for the quarter ending 2025-09-30 was $41.00K, a 0.00% change year-over-year.
- INMED PHARMACEUTICALS INC. amortization of intangible assets for fiscal 2023 was $159.23K, a 0.00% change from fiscal 2022.
- INMED PHARMACEUTICALS INC. amortization of intangible assets for fiscal 2022 was $159.23K, a 59.67% increase from fiscal 2021.
- INMED PHARMACEUTICALS INC. amortization of intangible assets for fiscal 2021 was $99.72K, a 13.86% increase from fiscal 2020.
- INMED PHARMACEUTICALS INC. amortization of intangible assets for fiscal 2020 was $87.59K.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 3 month as first filed | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 6 month as first filed | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 9 month as first filed | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $40.64K derived: S-4/A 12 month − S-4 9 month · filed 2026-09-09 | $81.64K derived: sum of 2 quarters · filed 2026-09-09 | $122.64K derived: sum of 3 quarters · filed 2026-09-09 | $162.64K S-4/A · filed 2026-09-09 | |||
| 2026-03-31 | $41.00K S-4 · filed 2026-07-02 | $82.00K derived: sum of 2 quarters · filed 2026-07-02 | $122.00K S-4 · filed 2026-07-02 | $163.64K derived: sum of 4 quarters · filed 2026-09-09 | |||
| 2025-12-31 | $41.00K 10-Q · filed 2026-02-11 | $82.00K 10-Q · filed 2026-02-11 | $122.64K derived: sum of 3 quarters · filed 2026-09-09 | $163.64K derived: sum of 4 quarters · filed 2026-09-09 | |||
| 2025-09-30 | $41.00K 10-Q · filed 2025-11-06 | $81.64K derived: sum of 2 quarters · filed 2026-09-09 | $122.64K derived: sum of 3 quarters · filed 2026-09-09 | $163.64K derived: sum of 4 quarters · filed 2026-09-09 | |||
| 2025-06-30 | $40.64K derived: S-4/A 12 month − S-4 9 month · filed 2026-09-09 | $81.64K derived: sum of 2 quarters · filed 2026-09-09 | $122.64K derived: sum of 3 quarters · filed 2026-09-09 | $162.64K S-4/A · filed 2026-09-09 | |||
| 2025-03-31 | $41.00K S-4 · filed 2026-07-02 | $40.10K 10-Q · filed 2025-05-12 | $82.00K derived: sum of 2 quarters · filed 2026-07-02 | $122.00K S-4 · filed 2026-07-02 | $122.09K 10-Q · filed 2025-05-12 | $172.33K derived: sum of 4 quarters · filed 2026-07-02 | |
| 2024-12-31 | $41.00K 10-Q · filed 2026-02-11 | $42.82K 10-Q · filed 2025-02-12 | $82.00K 10-Q · filed 2026-02-11 | $81.99K 10-Q · filed 2025-02-12 | $131.33K derived: sum of 3 quarters · filed 2026-07-02 | $172.32K derived: sum of 4 quarters · filed 2026-07-02 | |
| 2024-09-30 | $41.00K 10-Q · filed 2025-11-06 | $40.99K 10-Q · filed 2024-11-14 | $90.33K derived: sum of 2 quarters · filed 2026-07-02 | $131.32K derived: sum of 3 quarters · filed 2026-07-02 | $172.31K derived: sum of 4 quarters · filed 2026-07-02 | ||
| 2024-06-30 | $49.33K derived: S-4 12 month − 10-Q 9 month · filed 2026-07-02 | $90.32K derived: sum of 2 quarters · filed 2026-07-02 | $131.31K derived: sum of 3 quarters · filed 2026-07-02 | $171.86K S-4 · filed 2026-07-02 | |||
| 2024-03-31 | $40.99K 10-Q · filed 2025-05-12 | $81.99K derived: sum of 2 quarters · filed 2025-05-12 | $122.53K 10-Q · filed 2025-05-12 | $160.12K derived: sum of 4 quarters · filed 2025-05-12 | |||
| 2023-12-31 | $40.99K 10-Q · filed 2025-02-12 | $81.99K 10-Q · filed 2025-02-12 | $119.13K derived: sum of 3 quarters · filed 2025-02-12 | $159.23K derived: sum of 4 quarters · filed 2025-02-12 | |||
| 2023-09-30 | $40.99K 10-Q · filed 2024-11-14 | $78.13K derived: sum of 2 quarters · filed 2024-11-14 | $118.23K derived: sum of 3 quarters · filed 2024-11-14 | $159.23K derived: sum of 4 quarters · filed 2024-11-14 | |||
| 2023-06-30 | $37.14K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30 | $77.24K derived: sum of 2 quarters · filed 2024-09-30 | $118.23K derived: sum of 3 quarters · filed 2024-09-30 | $159.23K 10-K · filed 2024-09-30 | |||
| 2023-03-31 | $40.10K 10-Q · filed 2023-05-15 | $81.10K derived: sum of 2 quarters · filed 2024-02-13 | $122.09K 10-Q · filed 2023-05-15 | $235.89K derived: sum of 4 quarters · filed 2024-02-13 | |||
| 2022-12-31 | $40.99K 10-Q · filed 2024-02-13 | $81.99K 10-Q · filed 2024-02-13 | $195.78K derived: sum of 3 quarters · filed 2024-02-13 | $241.21K derived: sum of 4 quarters · filed 2024-02-13 | |||
| 2022-09-30 | $40.99K 10-Q · filed 2023-11-14 | $154.79K derived: sum of 2 quarters · filed 2023-11-14 | $200.22K derived: sum of 3 quarters · filed 2023-11-14 | $243.77K derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2022-06-30 | $113.80K derived: 10-K 6 month − 10-Q 3 month · filed 2023-09-29 | $159.23K 10-K · filed 2023-09-29 | $202.78K derived: sum of 3 quarters · filed 2023-09-29 | $159.23K 10-K · filed 2022-09-23 | |||
| 2022-03-31 | $45.43K 10-Q · filed 2023-05-15 | $88.98K derived: sum of 2 quarters · filed 2023-05-15 | $113.30K 10-Q · filed 2023-05-15 | $137.35K derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | $43.55K 10-Q · filed 2023-02-17 | $67.87K 10-Q · filed 2023-02-17 | $91.92K derived: sum of 3 quarters · filed 2023-02-17 | $115.70K derived: sum of 4 quarters · filed 2023-02-17 | |||
| 2021-09-30 | $24.32K 10-Q · filed 2022-11-14 | $48.37K derived: sum of 2 quarters · filed 2022-11-14 | $72.15K derived: sum of 3 quarters · filed 2022-11-14 | $102.44K derived: sum of 4 quarters · filed 2022-11-14 | |||
| 2021-06-30 | $24.05K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-23 | $47.84K derived: sum of 2 quarters · filed 2022-09-23 | $78.13K derived: sum of 3 quarters · filed 2022-09-23 | $99.72K 10-K · filed 2022-09-23 | |||
| 2021-03-31 | $23.79K 10-Q · filed 2022-05-13 | $54.08K derived: sum of 2 quarters · filed 2022-05-13 | $75.67K 10-Q · filed 2022-05-13 | $96.46K derived: sum of 4 quarters · filed 2022-05-13 | |||
| 2020-12-31 | $30.29K 10-Q · filed 2022-02-14 | $51.88K 10-Q · filed 2022-02-14 | $72.67K derived: sum of 3 quarters · filed 2022-02-14 | $94.06K derived: sum of 4 quarters · filed 2022-02-14 | |||
| 2020-09-30 | $21.60K 10-Q · filed 2021-11-10 | $42.38K derived: sum of 2 quarters · filed 2021-11-10 | $63.77K derived: sum of 3 quarters · filed 2021-11-10 | $85.76K derived: sum of 4 quarters · filed 2021-11-10 | |||
| 2020-06-30 | $20.79K derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-24 | $42.18K derived: sum of 2 quarters · filed 2021-09-24 | $64.16K derived: sum of 3 quarters · filed 2021-09-24 | $87.59K 10-K · filed 2021-09-24 | |||
| 2020-03-31 | $21.39K 10-Q · filed 2021-05-13 | $43.37K derived: sum of 2 quarters · filed 2021-05-13 | $66.80K 10-Q · filed 2021-05-13 | ||||
| 2019-12-31 | $21.98K 10-Q · filed 2021-02-11 | $45.43K 10-Q · filed 2021-02-11 | |||||
| 2019-09-30 | $23.45K 10-Q · filed 2020-12-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |